In response: The finding that misoprostol significantly reduced the frequently of both gastric and duodenal ulcer development in patients with arthritis who required long-term therapy with NSAIDs was established from a statistical comparison of two treatment groups and a randomized, placebo-controlled clinical trial (1) . The validity of that finding was not based on logistic regression modeling. Drs. Heudebert and McKinney question some of the study's peripheral and minor conclusions. To identify subgroups of patients receiving NSAIDs at increased risk for ulceration, we used logistic regression to examine the effects of the demographic and medical history measures. Gastric erosions and alcohol use had been suggested as possible risk factors. Heudebert and McKinney cite Concato and colleagues (2) , who based the 10:1 event-tovariable ratio on data from Harrell and associates (3) , who in turn refer to it only as a "rough rule of thumb." We agree that, because of the small number of outcomes, the possible effects of age, sex, and so forth might be missed. We also agree that care should be taken in both using and interpreting the results of multivariate statistical models. However, we do not agree that our conclusions were overstated. Importantly, none of the variables that we examined is known to be what Heudebert and McKinney call "important ulcerogenic risk factors." We doubt that the data as we presented it would mislead the reader. Our goal was to begin to identify high-risk patient subgroups that could be the focus of further studies. Our study lacked significant power to critically examine the small complementary role of these minor factors. The number of patients studied was sufficient to validly test the basic question and to establish the benefits of misoprostol therapy compared with placebo in reducing the development of gastric or duodenal ulcers in patients receiving long-term NSAID therapy.
David Y. Graham, MD Veterans Affairs Medical Center 2002 Holcombe Boulevard Houston, TX 77030

Delayed-Type Hypersensitivity and AIDS
To the Editors: The article by Blatt and colleagues (1) shows the prognostic significance of cutaneous delayed-type hypersensitivity testing in patients infected with human immunodeficiency virus (HIV). The excellent editorial by Kornbluth and McCutchan (2) discusses the Thl/Th2 switch that plays an important role in the loss of delayed-type hypersensitivity in HIV. Both articles focus on delayed-type hypersensitivity as a diagnostic tool in patients with the acquired immunodeficiency syndrome (AIDS).
The concept of using the cutaneous delayed-type hypersensitivity response as a therapeutic tool in patients with HIV has been discussed previously (3) . Topical dinitrochlorobenzene, a potent stimulant of the delayed-type hypersensitivity response, was suggested as treatment for AIDS in 1986. Since that time, long-term use of dinitrochlorobenzene by patients infected with HIV has been reported (4), and a pilot study of topical dinitrochlorobenzene treatment has been done (5). The theory underlying dinitrochlorobenzene use in patients with AIDS is that stimulation of cutaneous delayed-type hypersensitivity reverses the functional loss of antigen presentation that occurs during the course of the disease (3, 5) . This effect in turn reverses the Thl/Th2 switch responsible for anergy in patients infected with HIV, with consequent boosting of the cellular immune response against the virus (6).
It is time to think of cutaneous delayed-type hypersensitivity not just as a diagnostic tool but rather as the gateway to the immune system in patients with AIDS.
In response: Drs. Strieker and Elswood suggest the possible use of topical 2,4-dinitrochlorobenzene to induce allergic contact dermatitis in patients infected with HIV and thereby to modulate the cellular immune response against the virus (1). Although some evidence suggests that dinitrochlorobenzene may preferentially stimulate a Thl-like cytokine profile in mice (2) , no data exist to support such a mechanism in humans. On the contrary, we are concerned about the induction of nonspecific immunologic stimulation in patients infected with HIV because of the overwhelming evidence that immunologic activation is associated with a worsened prognosis in such patients (3) . Nonspecific T-cell activation may accelerate the course of HIV infection through several mechanisms, including the induction of programmed cell death (apoptosis) and up-regulation of HIV expression (4, 5 
Sensitivity and Specificity of the History and Physical Examination for Coronary Artery Disease
To the Editors: Pryor and colleagues have written a very interesting article (1); however, their data on sensitivity and specificity for each of the three diagnostic outcomes (significant disease, severe disease, and left main disease) are subject to verification or work-up bias. Their study sample included 1030 patients, but diagnostic outcomes were verified on only the 168 patients who subsequently had cardiac catheterization within 90 days. Because patients who "tested" positive (based on history and physical examination data) were more likely to have the gold standard evaluation (cardiac catheterization), the reported sensitivities are probably falsely high, and the reported specificities are probably falsely low.
The authors can correct for verification bias because they can calculate the "test" results within the group of patients who did not have the gold standard evaluation. I would be interested in seeing the corrected sensitivities and specificities for each of the three diagnostic test outcomes. In response: We appreciate the thoughtful comments of Dr. Evans regarding the potential for evaluation bias. Indeed, the predicted probabilities of significant, severe, and left main disease for patients who had cardiac catheterization were 0.68, 0.28, and 0.06, respectively, compared with 0.47, 0.18, and 0.04, respectively, in patients not referred for cardiac catheterization. As expected, patients unlikely to have these outcomes were not referred as often for diagnostic cardiac catheterization.
Arthur T. Evans, MD, MPH
Dr. Evans requested that we recalculate the sensitivity and specificity using the Bayesian approach to correct for the verification bias (1, 2) . Figure 1 shows the receiver operating curves for the assessment as presented in our article (3) with the recalculated receiver operating curve correcting for the "verification bias." The two curves are virtually identical. The receiver operating curves are calculated by varying the threshold above which the prediction of significant disease is considered to be a "positive" test result and below which the prediction of significant disease is considered to be a "negative" test result. The sensitivities and specificities vary when calculated for a particular cut point in correcting for the verification bias. Table 1 shows three examples in which thresholds for the likelihood of significant coronary disease are 25%, 50%, and 75%, respectively. At 50%, the sensitivity present in the study patients referred to catheterization was 90% and the specificity was 67%. When corrected for the verification bias, the sensitivity is 79%, and the specificity is 83%. Although the sensi- tivity and specificity vary in this example, the result is to move to a different place on the receiver operating curve.
We share Dr. Evans' concern about potential sources for bias. Clinicians wishing to apply probability models need to be concerned about three separate problems (4). The first is the method for generating estimates. The second is the overall quality of the probability prediction. This can be thought of in terms of reliability (how close a given prediction is to the actual value), discrimination (the ability to separate patients with and without the outcome of interest), and precision (the "random noise" or variation in the estimate). The third is generalizability (the likelihood that the results apply to an individual clinician's patient). Even if we had catheterized every patient attending the outpatient Cardiac Diagnostic Unit our patients differ from patients seen in a primary care practice. Consequently, some corrections would still be needed to use these estimates in general practice. 
Sensitivity, Specificity, Prevalence, and Disease Stage
To the Editors: When discussing the new diagnostic tests for sexually transmitted Chlamydia trachomatis infection, Stamm (1) writes that "Although none of these tests is as sensitive or specific as high-quality cultures for chlamydia, all have reasonable sensitivity (70% to 90%) and specificity (96% to 99%) in groups where the prevalence of chlamydial infection exceeds 8% to 10%." Sensitivity is defined as the percentage of diseased patients who are correctly identified as positive by a test. Specificity is the percentage of disease-free patients who are correctly identified as negative (2) . These test characteristics are not affected by the prevalence of disease. The author must have been referring instead to the predictive value of a positive test result and the predictive value of a negative test result, both of which vary according to the prevalence of disease in the population in which the test is applied.
John Terrell Redd, MD College of Physicians and Surgeons, Columbia University New York, NY 10032
In response: I appreciate Dr. Redd's comment and agree that, in a statistical sense, neither sensitivity nor specificity should vary with disease prevalence. However, with chlamydial infection (and others as well), biologic factors may influence the sensitivity and specificity of the test in populations having different prevalences (1, 2). For example, in patients infected with chlamydia who have recently acquired infection (usually seen in populations with a high prevalence), the number of organisms (and amount of antigen or DNA) present is greater than in populations characterized by low prevalence. In the latter populations, more infections are long-lived, are subacute, and characterized by fewer chlamydial organisms. Hence, test performance will change because infections will be more difficult to detect in a population composed largely of patients harboring fewer organisms.
Walter E. Stamm, MD
Harborview Medical Center Seattle, WA 98104
Nitric Oxide Synthesis in Meningococcal Meningitis
To the Editors: Clinical meningitis arises largely from the inflammatory response to bacteria invading the cerebrospinal fluid. Because nitric oxide, an endogenous mediator with vasodilator, neurotransmitter, and cytotoxic activities may be involved (1), we measured cerebrospinal fluid levels of nitrate and nitrite, the stable degradation products of nitric oxide, in 94 patients with meningococcal meningitis and in 44 patients with noninflammatory neurologic disease.
Controls had mean cerebrospinal fluid nitrate levels of 6.3 fimo\/L (range, 2.3 to 17.3 /xmol/L) and nitrite levels of 0.5 jLtmol/L (range, 0.4 to 1.7 /xmol/L). Compared with controls, patients with meningitis had a mean nitrate level of 18.4 /xmol/L (range, 3.1 to 150.7 /xmol/L) and a mean nitrite level of 25.8 timol/L (range, 0.2 to 330.2 /rniol/L) (P < 0.001, MannWhitney test). Because Neisseria meningitidis is not known to form nitrate or nitrite, these increases must have resulted from increased endogenous production through the only known metabolic route for their formation in body tissues, namely degradation of nitric oxide (2) . Our findings show that nitric oxide synthesis is induced in cells within the central nervous system compartment in response to bacterial invasion.
The pathophysiologic significance of the local increase in nitric oxide remains to be elucidated. High levels of nitric oxide are known to be toxic to endothelial cells and neurons (3, 4) ; consequently, local increases in nitric oxide may play a role in the microvascular damage and the neurologic sequelae of meningitis. If so, treatment with specific inhibitors of inducible nitric oxide synthesis might be beneficial in patients with bacterial meningitis.
Creative Part-Time Faculty Arrangements
To the Editors: I read with great interest the article on parttime faculty in academic medicine (1) . During the past 4 years, I have served as Director of the Medical Residents Clinic and Director of the Third Year Medicine Clerkship and have participated in inpatient rounds. Through these responsibilities, I have significant contact with residents and students as a teacher and role model. After the birth of my first child last year, I felt constantly sleep-deprived, frustrated, and overwhelmed by the demands on my time. I quickly realized that I was no longer a positive role model but rather a clear example to residents and students that general internal medicine is too demanding to allow a successful balance of career and family goals.
I planned to leave academic medicine to accept a part-time private practice position but instead negotiated with my Chairman a change to part-time faculty status and a continuation of many of my previous responsibilities. Since July, I have been working 25 to 30 hours per week. My personal satisfaction has skyrocketed, and I have renewed enthusiasm for patient care and teaching. If we are to heighten the appeal of generalist careers to the ever-increasing numbers of women in medicine, our academic institutions must meet this challenge by providing satisfied role models. By supporting part-time faculty members and by developing policies for promotion and time-totenure, academic institutions will enhance career satisfaction for those physicians choosing part-time work to balance family obligations and will provide appealing role models. To the Editors: In response to the study by Levinson and colleagues (1), we describe a model that has worked well at the Medical College of Wisconsin.
In July 1985, the Division of General Internal Medicine required additional personnel. Three female physicians independently requested part-time work because of family responsibilities. The division chief and the administration agreed to allow all three women to work part-time, which was defined as 50% to 70% of full-time. The benefits included prorated vacation and sick leave, with the option of participating in the retirement plan. Malpractice was not paid, and no policy was created regarding promotion or tenure.
The part-time option steadily gained acceptance; other physicians chose to reduce their hours, and new part-time physicians were hired. By 1987, malpractice insurance had become prohibitively expensive. To meet the part-time faculty's need for paid malpractice coverage, a formal College faculty category called "full professional effort" was created. In this classification, all of a person's professional effort was under the College's auspices. Individuals in this category work at least half-time or more than 1000 hours per year. Malpractice coverage is paid, as are prorated vacation, sick leave, and retirement. The full professional effort faculty are promoted on the clinician-educator track, and the allowable time at each faculty rank is prorated according to percentage of effort.
Since allowing part-time work in 1985, no part-time faculty member has left our division. All part-time faculty appreciate the flexibility this arrangement has allowed them in balancing career and family.
In response: We congratulate Dr. Ziring and her Chair for negotiating a change to part-time status. Many women drop out of academia to find feasible ways to juggle the responsibilities of motherhood and medicine, resulting in a loss of potential creativity and productivity for academic institutions. Others, in their endeavor to be all things to all people, become so frustrated that the negatives outweigh the positives.
Several medical schools are developing policies to accommodate faculty who prefer to work less than 100% for a given period. The model described by Drs. Tesch and Nattinger is a good example. The faculty of George Washington University School of Medicine has approved similar "full professional effort" provisions (Keimowitz R. Personal Communication). Also, Yale University School of Medicine allows tenure track faculty to work less than 100%, extending the usual 10-year probationary period to a maximum of 13 years (Waxman M. Personal Communication). The University of Pennsylvania School of Medicine allows a similar extension for tenure-track faculty (Parris M. Personal Communication).
We hope that Deans and Department Chairs will adapt their faculty policies to allow their energetic junior female faculty members to contribute their best to academic medicine; both male and female students need these role models. Moreover, our the number of adults 45 years of age or older in Latin America will increase from 67 million to 169 million (150%) compared with a 4% increase in children 0 to 4 years of age. As the life expectancy at birth increases in developing countries, the adult population will face the same chronic and debilitating illnesses now afflicting older patients in the highly industrialized world. Given their limited resources, Latin American physicians and governments will be severely challenged to use technology cost-effectively. A recent development aimed at educating physicians to use resources optimally prompts my letter.
The first issue of the monthly Spanish-language Annals of Internal Medicine has just been published. Its existence has been made possible by a collaboration of the publishing company Intermedica and the Editors and staff of Annals. The journal is currently being piloted in selected countries. The journal will make Spanish-language translations of pertinent articles available to thousands of physicians who would otherwise not have access to the information available in the English-language version of Annals. I am certain that millions of adult patients of the Spanish-speaking world will benefit from this educational opportunity.
Humberto Vidaillet, Jr., MD Marshfield Clinic Marshfield, WI 54449-5777
Misclassification of Clonidine
To the Editors: In their recent review of drug-induced disorders of glucose tolerance, Pandit and colleagues (1) state that clonidine is a centrally acting a-blocker. However, this is an error. Clonidine is, in fact, classified as a selective a-2 agonist. The blood pressure-lowering effects of clonidine result from activation of a-2 receptors in the central nervous system, which reduces sympathetic outflow (2).
Ila V. Mehra, PharmD
Medical University of South Carolina Charleston, SC 29425
